Locoregional control after breast conserving treatment in patients undergoing neoadjuvant chemotherapy for breast cancer

3^rd World Congress on Women’s Health & Breast Cancer

October 03-05, 2016 London, UK

Margherita Serra, Andrea Sibilio, Donatella Santini, Maddalena Rocchi, Alice Pellegrini, Simone Zanotti and Mario Taffurelli

Policlinico Sant'Orsola-Malpighi, Italy

Posters & Accepted Abstracts: J Cancer Sci Ther

Abstract :

Introduction: Limited information on rates and predictors of locoregional recurrence (LRR) and ipsilateral breast tumor recurrence (IBTR) for patients who undergo NAC are available. The aim of this analysis is to compare a population of patients treated with BCT and axillary lymph node dissection after NAC (NAC-group), with a consecutive case series of patients also treated with BCT and ALND for which NAC was not indicated. Methods: 532 patients were treated with BCT and ALND for breast cancer at Sant�Orsola-Malpighi Breast Unit, between 2000 and 2014: 84 with NAC first, 448 underwent surgery upfront and adjuvant chemotherapy. Measured outcomes were 5 and 10 years IBTR-free survival and LRR-free survival. Results obtained were compared to a population of patients treated with BCT and ALND, for whom NAC was not indicated (PoCT-group). Results: 32/448 cases of IBTR were registered among patients treated with BCT and adjuvant chemotherapy, while 9/84 cases were registered in the NAC-group. LRR occurred in 37 patients in the PoCT-group and in 9 patients in the NACgroup. 5 years LRR-free survival for NAC group resulted 87.4% vs. 95.3% in PoCT-group; while 10 years LRR-free survival was respectively 79.4% and 89.3%. 5 years IBTR-free survival for NAC group resulted 87.5% vs. 95.3% in PoCT-group; while 10 years IBTRfree survival was respectively 79.5% and 88.9%. In patients initially staged cT2, there was no significant difference in terms of outcome at 5 and 10 years. For PoCT-group vs. NAC, 5 years LRR-free survival respectively was 94.9% vs. 90.2%, and 10 years LRR-free survival respectively was 91.7% vs. 78.9%. In terms of IBTR, 5 years and 10 years IBTR free survivals were 90.2% vs. 94.9% and 78.9% vs. 91.7%, p=0.14. DFS at 5 and 10 years for PoCT vs. NAC-group, as predictable was significantly different, respectively 88.9% vs.77% 5 yrs DFS and 75.1% vs. 59.8% 10 yrs DFS. While 5 years OS resulted 93% vs. 86.2% and 10 years OS resulted 83% vs. 83.5%, respectively. Conclusions: NAC shows equivalent outcomes obtained with BCT and adjuvant chemotherapy.

Biography :

Email: magserra@hotmail.com